Quarterly report pursuant to Section 13 or 15(d)

SETTLEMENT LIABILITY (Details Narrative)

v3.23.2
SETTLEMENT LIABILITY (Details Narrative) - REGENXBIO [Member] - USD ($)
$ in Millions
6 Months Ended 12 Months Ended
Nov. 12, 2021
Jun. 30, 2023
Dec. 31, 2022
Defined Benefit Plan Disclosure [Line Items]      
Settlement liabilities, current $ 30.0    
Loss contingency settlement agreement terms (1) $20.0 million paid in November 2021 after execution of the Settlement Agreement, (2) $5.0 million on the first anniversary of the effective date of the Settlement Agreement, and (3) $5.0 million upon the earlier of (i) the third anniversary of the effective date of the Settlement Agreement or (ii) the closing of a Strategic Transaction, as defined in the Settlement Agreement    
Interest rate stated percentage   9.60%  
Due In November 2024 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Debt instrument maturity date   November 2024 November 2024
Long term debt   $ 4.4 $ 4.2